Q32 Bio Inc. (QTTB)
Oxford Ledge is still expanding full research coverage of QTTB. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biotech company developing bempikibart, an IL-7 receptor antagonist monoclonal antibody for autoimmune diseases like alopecia areata.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-07-13
- 8-K Shareholder vote results 2026-06-16
- 8-K Entry into material agreement; 3.02; Other material event; Financial statements and exhibits 2026-05-27
- 10-Q Quarterly financial report (unaudited) 2026-05-05
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-05
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for QTTB. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open QTTB in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.